新辅助化疗后乳腺病理完全缓解与腋窝病理完全缓解的关联性
Correlation between breast and axillary pathologic complete response after neoadjuvant chemotherapy

DOI: 10.6040/j.issn.1671-7554.0.2017.1094

Keywords: 乳腺癌,腋窝淋巴结,新辅助化疗,病理完全缓解,
Breast cancer,Axillary lymph node,Neoadjuvant chemotherapy,Pathologic complete response

Full-Text   Cite this paper   Add to My Lib

Abstract:

References

[1]	Mamounas EP, Brown A, Anderson S, et al. Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer: Results from national surgical adjuvant breast and bowel project protocol b-27[J]. J Clin Oncol, 2005, 23(12): 2694-2702.
[2]	Gianni L, Eiermann W, Semiglazov V, et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with her2-positive locally advanced breast cancer(the noah trial): A randomised controlled superiority trial with a parallel her2-negative cohort[J]. Lancet, 2010, 375(9712): 377-384.
[3]	Buzdar AU, Valero V, Ibrahim NK, et al. Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: An update of the initial randomized study population and data of additional patients treated with the same regimen[J]. Clin Cancer Res, 2007, 13(1): 228-233.
[4]	Edge SB, Byrd DR, Compton CC, et al. AJCC Cancer Staging Manual, 7th Edition[M]. New York: Springer, 2010.
[5]	van la Parra RF, Kuerer HM. Selective elimination of breast cancer surgery in exceptional responders: Historical perspective and current trials[J]. Breast Cancer Res, 2016, 18(1): 28.
[6]	Goldhirsch A, Winer EP, Coates AS, et al. Personalizing the treatment of women with early breast cancer: Highlights of the st gallen international expert consensus on the primary therapy of early breast cancer 2013[J]. Ann Oncol, 2013, 24(9): 2206-2223.
[7]	Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit in breast cancer: The ctneobc pooled analysis[J]. Lancet, 2014, 384(9938): 164-172.
[8]	Bayraktar S, Gonzalez-Angulo AM, Lei X, et al. Efficacy of neoadjuvant therapy with trastuzumab concurrent with anthracycline- and nonanthracycline-based regimens for her2-positive breast cancer[J]. Cancer, 2012, 118(9): 2385-2393.
[9]	Untch M, Fasching PA, Konecny GE, et al. Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: Results from the techno trial of the ago and gbg study groups[J]. J Clin Oncol, 2011, 29(25): 3351-3357.
[10]	Zhang GC, Zhang YF, Xu FP, et al. Axillary lymph node status, adjusted for pathologic complete response in breast and axilla after neoadjuvant chemotherapy, predicts differential disease-free survival in breast cancer[J]. Curr Oncol, 2013, 20(3): 180-192.
[11]	Stoetzer OJ, Fersching DM, Salat C, et al. Circulating immunogenic cell death biomarkers hmgb1 and rage in breast cancer patients during neoadjuvant chemotherapy[J]. Tumour Biol, 2013, 34(1): 81-90.
[12]	Kuerer HM, Rauch GM, Krishnamurthy S, et al. Abstract p5-16-30: Feasibility trial for identification of patients for eliminating breast cancer surgery following neoadjuvant systemic therapy[J]. Cancer Research, 2017, 77(4 Supplement): P5-16-30.
[13]	Tadros AB, Yang WT, Krishnamurthy S, et al. Identification of patients with documented pathologic complete response in the breast after neoadjuvant chemotherapy for omission of axillary surgery[J]. JAMA Surg, 2017, 152(7): 665-670.
[14]	Pilewskie M, Morrow M. Axillary nodal management following neoadjuvant chemotherapy: A review[J]. JAMA Oncol, 2017, 3(4): 549-555.
[15]	Vera-Badillo FE, Templeton AJ, de Gouveia P, et al. Androgen receptor expression and outcomes in early breast cancer: A systematic review and meta-analysis[J]. J Natl Cancer Inst, 2014, 106(1): 319.
[16]	Hennessy BT, Hortobagyi GN, Rouzier R, et al. Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy[J]. J Clin Oncol, 2005, 23(36): 9304-9311.
[17]	Saxena N, Hartman M, Aziz R, et al. Prognostic value of axillary lymph node status after neoadjuvant chemotherapy. Results from a multicentre study[J]. Eur J Cancer, 2011, 47(8): 1186-1192.
[18]	Ohno S, Chow LW, Sato N, et al. Randomized trial of preoperative docetaxel with or without capecitabine after 4 cycles of 5-fluorouracil- epirubicin-cyclophosphamide(fec)in early-stage breast cancer: Exploratory analyses identify ki67 as a predictive biomarker for response to neoadjuvant chemotherapy[J]. Breast Cancer Res Treat, 2013, 142(1): 69-80.
[19]	Nwaogu IY, Fayanju OM, Jeffe DB, et al. Predictors of pathological complete response to neoadjuvant chemotherapy in stage ii and iii breast cancer: The impact of chemotherapeutic regimen[J]. Mol Clin Oncol, 2015, 3(5): 1117-1122.

Full-Text